Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: A review

Clinical Pharmacology: Advances and Applications

Volumn 2, Issue 1, 2010, Pages 111-122

  Reh, Christina Southern ^a   Geffner, Mitchell E ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Growth hormone; Pediatric patients; Somatotropin; Turner syndrome

Indexed keywords

ARGININE; CLONIDINE; ETHINYLESTRADIOL; GENE PRODUCT; GLUCAGON; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; INSULIN; LEVODOPA; PLACEBO; SHORT STATURE HOMEOBOX; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

BONE AGE; BONE GROWTH; BRAIN PSEUDOTUMOR; BREAST DEVELOPMENT; CHROMOSOME LOSS; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DISEASE MARKER; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; DRUG STRUCTURE; EPIPHYSIOLYSIS; GENETIC DISORDER; GROWTH DISORDER; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEART DISEASE; HISTORY OF MEDICINE; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; HYPOTHYROIDISM; INCIDENCE; INFERTILITY; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TOLERANCE TEST; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; LYMPHEDEMA; MONOSOMY; NAUSEA; NECK MALFORMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PAPILLEDEMA; PATHOPHYSIOLOGY; PREMATURE OVARIAN FAILURE; PRIMARY AMENORRHEA; REVIEW; SCREENING TEST; SHORT STATURE; TREATMENT INDICATION; TURNER SYNDROME; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 77955486117     PISSN: None     EISSN: 11791438     Source Type: Book Series    
DOI: None     Document Type: Review

References (77)

1. Grumbach MM, Bin-Abbas BS, Kaplan SL. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency. Horm Res. 1998;49 Suppl 2:41-57.
2. Baumann G P. Growth hormone isoforms. Growth Horm IGF Res. 2009;19(4):333-340.
3. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord. 2001;25 Suppl 5: S63-S67.
4. Lengyel AM. Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res. 2006;39(8):1003-1011.
5. Cohen P, Rosenfeld RG. Physiologic and clinical relevance of the insulin-like growth factor binding proteins. Curr Opin Pediatr. 1994;6(4):462-467.
6. Melhus H, Ljunghall S. Growth hormone and insulin-like growth factor-I do not activate identical genes in normal human osteoblasts. Biochem Mol Biol Int. 1996;38(2):425-428.
7. Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation. 1985;29(3):195-198.
8. Gevers EF, Hannah MJ, Waters MJ, Robinson IC. Regulation of rapid signal transducer and activator of transcription-5 phosphorylation in the resting cells of the growth plate and in the liver by growth hormone and feeding. Endocrinology. 2009;150(8):3627-3636.
9. Eugster EA, Pescovitz OH. New revelations about the role of STATs in stature. N Engl J Med. 2003;349(12):1110-1112.
10. Gertner JM. Growth hormone actions on fat distribution and metabolism. Horm Res. 1992;38 Suppl 2:41-43.
11. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901-903.
12. Frasier SD. The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr. 1997;131(1 Pt 2):S1-S4.
13. Goeddel DV, Heyneker HL, Hozumi T, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281(5732):544-548.
14. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1-9.
15. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone defcient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf). 1993;38(2):137-142.
16. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. Endocrinol Metab Clin North Am. 2009;38(3):587-611.
17. Ranke MB. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars. Horm Res. 2008; 69(1):22-28.
18. Mullis PE, Deladoey J, Dannies PS. New GH-1 gene mutations: expanding the spectrum of causes of isolated growth hormone deficiency. J Pediatr Endocrinol Metab. 2002;15 Suppl 5:1301-1310.
19. Dubourg C, Bendavid C, Pasquier L, Henry C, Odent S, David V. Holoprosencephaly. Orphanet J Rare Dis. 2007;2:8.
20. Yamanaka C, Momoi T, Fujisawa I, et al. Acquired growth hormone deficiency due to pituitary stalk transection after head trauma in childhood. Eur J Pediatr. 1993;152(2):99-101.
21. Bocca G, van Beek A P, de Bont ES. [Grow hormone deficiency in children after radiation for a brain tumor. Quickly start with substitution]. Ned Tijdschr Geneeskd. 2009;153(17):792-793.
22. Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Horm IGF Res. 2006;16 Suppl A:S30-S40.
23. Mouridsen SE, Nielsen S. Reversible somatotropin deficiency (psychosocial dwarfism) presenting as conduct disorder and growth hormone deficiency. Dev Med Child Neurol. 1990;32(12):1093-1098.
24. Rosenfeld RG, Pham H, Cohen P, et al. Insulin-like growth factor binding proteins and their regulation. Acta Paediatr Suppl. 1994;399:154-158.
25. Tanaka T. Global situation of growth hormone treatment in growth hormone-deficient children. Horm Res. 1999;51 Suppl 3:75-80.
26. Frasier SD. A preview of growth hormone stimulation tests in children. Pediatrics. 1974;53(6):929-937.
27. Shah A, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ. 1992; 304(6820): 173-174.
28. Bonfig W, Bechtold S, Bachmann S, et al. Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab. 2008;21(11):1049-1056.
29. Wilson DM, Baker B, Hintz RL, Rosenfeld RG. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response. Pediatrics. 1985;76(3):361-364.
30. Milner RD, Russell-Fraser T, Brook CG, et al. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol (Oxf). 1979;11(1):15-38.
31. Kastrup K W, Christiansen JS, Andersen JK, Orskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh). 1983;104(2):148-152.
32. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. 1990; 70:207-214.
33. Bertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand. 1986;75:89-97.
34. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab. 1996;81: 1806-1809.
35. Ranke MB, Schweizer R, Wollmann HA, Schwarze P. Dosing of growth hormone in growth hormone deficiency. Horm Res. 1999;51 Suppl 3:70-74.
36. Jorgensen JO, Moller J, Moller N, Lauritzen T, Christiansen JS. Pharmacological aspects of growth hormone replacement therapy: route, frequency and timing of administration. Horm Res.1990;33 Suppl 4:77-82.
37. Codner E, Mericq V, Cassorla F. Optimizing growth hormone therapy during puberty. Horm Res. 1997;48 Suppl 5:16-20.
38. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab. 2000;85(10):3653-3660.
39. Saenger P. Dose effects of growth hormone during puberty. Horm Res. 2003;60 Suppl 1:52-57.
40. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res. 2004;62 Suppl 1:59-65.
41. Zucchini S, Pirazzoli P, Baronio F, et al. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab. 2006;91(11):4271-4276.
42. Saggese G, Baroncelli GI. Bone mineral density and biochemical parameters of bone turnover in children with growth hormone deficiency. Horm Res. 1996;45 Suppl 1:67-68.
43. Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab. 2003;88(11):5273-5280.
44. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152(1): 67-75.
45. Colao A, Di SC, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002;87(8):3650-3655.
46. Lanes R, Paoli M, Carrillo E, Villaroel O, Palacios A. Cardiovascular risk of young growth-hormone-deficient adolescents. Differences in growth-hormone-treated and untreated patients. Horm Res. 2003;60(6):291-296.
47. Geffner ME. Transition to the adult endocrine clinic: testing pituitary function-what tests and when? Growth Horm IGF Res. 2003;13 Suppl A:S117-S121.
48. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency. Growth Horm IGF Res. 2001;11(3):137-165.
49. Cutfield W, Lindberg A, Albertsson WK, Chatelain P, Ranke MB, Wilton P. Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta Paediatr Suppl. 1999;88(428):72-75.
50. Westphal O, Lindberg A. Final height in Swedish children with idiopathic growth hormone deficiency enrolled in KIGS treated optimally with growth hormone. Acta Paediatr. 2008;97(12):1698-1706.
51. Root AW, Kemp S F, Rundle AC, Dana K, Attie KM. Effect of long-term recombinant growth hormone therapy in children-the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab. 1998;11(3):403-412.
52. Geffner ME, Dunger DB. Future directions: growth prediction models. Horm Res. 2007;68 Suppl 5:51-56.
53. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151(6):657-687.
54. Davenport ML, Punyasavatsut N, Gunther D, Savendahl L, Stewart P W. Turner syndrome: a pattern of early growth failure. Acta Paediatr Suppl. 1999;88(433):118-121.
55. Ranke MB, Stubbe P, Majewski F, Bierich JR. Spontaneous growth in Turner's syndrome. Acta Paediatr Scand Suppl. 1988;343:22-30.
56. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16(1):54-63.
57. Blaschke RJ, Rappold G. The pseudoautosomal regions, SHOX and disease. Curr Opin Genet Dev. 2006;16(3):233-239.
58. Ogata T. SHOX haploinsufficiency and its modifying factors. J Pediatr Endocrinol Metab. 2002;15 Suppl 5:1289-1294
59. Cavallo L, Gurrado R. Endogenous growth hormone secretion does not correlate with growth in patients with Turner's syndrome. Italian Study Group for Turner Syndrome. J Pediatr Endocrinol Metab. 1999; 12(5):623-627.
60. Blum WF, Cao D, Hesse V, et al. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res. 2009;71(3): 167-172.
61. Ito Y, Fujieda K, Tanaka T, et al. Low-dose growth hormone treatment (0.175 mg/kg/week) for short stature in patients with Turner Syndrome: data from KIGS Japan. Endocr J. 2006;53(5):699-703.
62. Van Pareren YK., De Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88(3):1119-1125.
63. McCarthy K, Bondy CA. Turner syndrome in childhood and adolescence. Expert Rev Endocrinol Metab. 2008;3(6):771-775.
64. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87(5):2033-2041.
65. Ranke MB, Lindberg A, Ferrandez LA, et al. Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res. 2007;61(1):105-110.
66. Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92(9):3406-3416.
67. Morin A, Guimarey LM, Apezteguia M, Santucci ZC. Adult height in Turner Syndrome girls after long-term growth hormone treatment. Medicina (B Aires). 2009;69(4):431-436.
68. Stephure DK. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90(6):3360-3366.
69. De MKS, Van den BJ, Sas T, Hokken-Koelega A. Final height of growth hormone-treated GH-deficient children and girls with Turner's syndrome: the Dutch experience. The Dutch Advisory Group on Growth Hormone. Horm Res. 1999;51 Suppl 3:127-131.
70. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68 Suppl 5:41-47.
71. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab. 1998;83(8): 2824-2829.
72. Agha A, Monson J P. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol (Oxf). 2007;66(4): 459-465.
73. Agha A, Walker D, Perry L, et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf). 2007;66(1):72-77.
74. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355(9204): 610-613.
75. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167-177.
76. Ahmed S F, Smith WA, Blamires C. Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis. Arch Dis Child. 2008;93(2):110-114.
77. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003;143(4):415-421.